Key Findings
The administration of a CRISPR adenine base editor resulted in durable, liver-selective inactivation of angiopoietin-like 3 (ANGPTL3). In nonhuman primates, a single dose led to a mean reduction in circulating ANGPTL3 protein of > 90%, with effects persisting for 3 years. In both mouse and nonhuman primate models of hyperlipidemia, this gene inactivation was associated with reductions of approximately 40 to 50% in low-density lipoprotein cholesterol (LDL-C) and 50 to 70% in triglycerides.
Technical Details
The treatment utilizes a GalNAc–lipid nanoparticle (LNP) to encapsulate guide RNA and mRNA encoding the CRISPR adenine base editor. This delivery system enables liver-selective targeting. In vitro analyses using human liver cells confirmed that the base editor introduces a DNA base-pair change at the target ANGPTL3 locus. Safety assessments showed no detectable off-target editing across approximately 3000 candidate sites, nor were any treatment-related structural variants detected.
Background & Context
Circulating concentrations of LDL-C and triglyceride-rich lipoproteins are primary risk factors for atherosclerotic cardiovascular disease. While various lipid-lowering medications are approved, the chronic care treatment model often fails to help most patients achieve target lipid levels. ANGPTL3 is identified as a known driver that increases both LDL-C and triglyceride concentrations, making it a strategic target for permanent or durable inactivation.
Significance & Outlook
By shifting from chronic medication to a potential single-course treatment, this approach addresses the limitations of current lipid-management models. The durability and precision demonstrated in nonhuman primates and human liver cells have led to the initiation of an ongoing first-in-human clinical trial. This trial focuses on patients suffering from refractory hyperlipidemia syndromes.
Source: https://doi.org/10.1038/s41586-026-11233-9
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



